Hello everyone! Today i want to share some ai trading ideas with you! 1 Elon Musk says $SpaceX(SPCX)$ is aiming for “30+ Starship launches/day in 2030” or roughly 10,000 launches a year. That would represent a completely different scale for spaceflight with Starship launching more than once an hour. 2 $SpaceX(SPCX)$ and $AST SpaceMobile, Inc.(ASTS)$ are reportedly eyeing ~$6B of 800 MHz spectrum that could strengthen their push into satellite direct-to-device service. The licenses cover nearly the entire U.S. population with preliminary bids due in early September and the FCC targeting a Nov. 5 completion. 3

MY $Alibaba(BABA)$ VALUATION MODEL PRICE TARGET: $192 --> $203 POTENTIAL UPSIDE: +61% ✅ "The stock remains undervalued modeling $100B cloud revenue in 5 years and a decent operating leverage" ASSUMPTIONS: LTM Revenue: $149.282B (𝘢𝘴𝘴𝘶𝘮𝘪𝘯𝘨 𝘜𝘚𝘋/𝘊𝘕𝘠 = 𝟩.00) 5Y Revenue CAGR: 10% 2031 Profit Margin: 17% 2031 PE Ratio: 18 Shares outstanding: 2.416B Shares reduction: 1%/year VALUATION: Q2 2031 $Alibaba(BABA)$ SHARE PRICE =149.282 * (1.10)^5 * 0.17 * 18 /[2.416 * (0.99)^5] = $320 You can now choose the discount rate that you prefer, for Alibaba I want to use 12% ACTUAL PRICE: $128 FAIR VALUE: $182 PRICE TARGET (1Y): $203 POTENTIAL UPSIDE: 61% EXPECTED RETURNS: 20.1%/year DIVIDEND

$Tempus AI(TEM)$ is still wildly undervalued. Here's how I think the business should be valued over the next 12 months: DATA & APPLICATIONS -> Annualized revenue based on Q2 is currently ~$410M. Growth at a similar rate into FY27 would put us at $525M. -> This business has 73% gross margins so at 28% YoY growth and those margins it's putting up figures like a solid SaaS company. -> $525M * 10x sales = $5.3B -> $525M * 12x sales = $6.3B DIAGNOSTICS -> Generated $293.3M in Q2 alone which is $1.2B annualized. Growth at a similar rate gets us to $1.5B in FY27. -> And plus, $Tempus AI(TEM)$ recently received FDA approval on xT CDx test which brings tumor DNA

Humanoids are coming and there are three public options now. We have Unitree (688836) now public at $53B. -> 2025 revenue ~$250M (humanoids were half of that). -> 2025 humanoid shipments ~ 5,500. -> ASPs ~$24k -> Production already demonstrated in the multi-thousand unit annual output range. Nomura has already initiated a 25x (yes...25x) 2027 P/S multiple for Unitree. We have $Churchill Capital Corp XI(CCXI)$ (Agility) expected to go public at $2.5B pre-money. -> Trailing annual revenue ~$37M -> Cash burn ~$100M -> 150 units but 65,000 real world hours -> ~$125k BOM with a path to $30k long0term -> $300M multi-year contracted order. And we have Optimus /

Hello everyone! Today i want to share some trading ideas with you! 9:40am, Aug. 14, my 2-hr TOP KILLER signal flashed RED ALERT, and I opened some short-term puts & have closed ALL of them today. A few sessions generated 170+ SPX points, which is quite remarkable--esp. since this indicator rarely flashes; but, if it does, look out below. $S&P 500(.SPX)$

Just want to add to this $Amazon.com(AMZN)$ math: E-Commerce: ARR is currently $547B. It's likely worth anywhere between 1 -1.8x sales which puts the e-comm valuation ~$800B. Digital Ads: FY26 revs is heading towards $80B+ with operating margins likely at +50% which puts operating income +$40B. I think a conservative multiple on this is in the 20x EBIT range which values the ads business ~$800B as well. That's a total of $1.6T in e-comm and ads. Overall valuation is $2.8T which means ~$1.2T is available for: -> AWS: Likely worth +$3T by 2030 -> Amazon Leo -> Zoox -> One Medical -> Prime Video -> Equity stakes

Just some back of the napkin maths on $Amazon.com(AMZN)$from MS: $Amazon.com(AMZN)$ AWS: AWS Q2 2026 revenue came in at $42.2B. That's an annualized run rate of $169B. $Amazon.com(AMZN)$ management have said it's very possible AWS reaches a $1T annual revenue business. Constraint is entirely capacity driven with a huge $496B backlog. But let's model out the path to $1T in annual revs: Capacity ~14 GW in 2025 -> 120 GW in 2035. -> ~6 GW in 2026 and then ~8 GW per year thereafter. -> Monetization rises to ~$12 revenue per incremental watt. -> Which means at $12/W, each 8 GW of new capacity adds $96B in ann

𝙈𝙔 $Regeneron Pharmaceuticals(REGN)$ 𝙑𝘼𝙇𝙐𝘼𝙏𝙄𝙊𝙉 𝙈𝙊𝘿𝙀𝙇 1Y TARGET: $1060 POTENTIAL UPSIDE: +31% ✅ ASSUMPTIONS: LTM Revenue: $15.535B 5Y Revenue CAGR: 10% 2031 Profit Margin: 35% 2031 PE Ratio: 17 Shares outstanding: 106.0M Shares reduction: 2%/year VALUATION: Q2 2031 $Regeneron Pharmaceuticals(REGN)$ SHARE PRICE =15.535 * (1.10)^5 * 0.35 * 17 /[0.1060 * (0.98^5)] = $1554 You can now choose the discount rate that you prefer, for Regeneron I want to use 10%. ACTUAL PRICE: $810 FAIR VALUE: $965 PRICE TARGET (1Y): $1060 POTENTIAL UPSIDE: +31% EXPECTED RETURNS: 13.9%/year DIVIDEND YIELD: 0.5% - - - - - - - - - - - - - - - 𝘛𝘩𝘪𝘴 𝘱𝘰𝘴𝘵 𝘪𝘴 𝘧𝘰𝘳 𝘪𝘯𝘧𝘰𝘳𝘮𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘢𝘯𝘥 𝘦𝘥𝘶𝘤𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘱𝘶𝘳𝘱𝘰𝘴𝘦𝘴 𝘰𝘯𝘭𝘺

Here's my 2030 $NEBIUS(NBIS)$ estimate: -> 5GW capacity is contracted by YE 26 with 1GW capacity to be deployed per year from FY 27. -> Mid-term ACV is ~$20-25M as per management (for reference it used to be ~$12M). So a BULL case model would look something like this: 5.2 GW connected capacity by 2030 on a blended ARR/MW of $14M (that's a realistic haircut on utilization, mix, and timing vs the $20-25M forecasted. 5,200 MW * $14M = $72.8B ARR With EBITDA margins forecasted to stabilize near 45%... we're then looking at ~$32.7B in EBITDA. Bull case multiple: 25x Base case multiple: 18x Bear case multiple: 13x 25x * $32.7B -> $817B 18x * $32.7B -> $588B 13x * $32.7B -> $425B Or go more conservative (which is fair) and